Abstract: The present invention relates to sterile and desiccated biomaterials comprising devitalized differentiated cells having tissue regenerating and/or repairing properties, and a particulate material, the cells and the particulate material being embedded in an extracellular matrix. The particulate material is preferably gelatin, a ceramic material, or a demineralized bone matrix (DBM).

Abstract: The present invention relates to a pharmaceutical composition for use in the prevention and/or the treatment of cancer and/or inflammation, comprising (i) a cellular and/or extracellular extract(s) obtained from a scaffold-free 3-dimensional culture of mature cells and a particulate material, wherein the mature cells secreted an extracellular matrix, and wherein the mature cells and the particulate material were embedded in the extracellular matrix; and (ii) a pharmaceutically acceptable excipient.

Abstract: The present invention relates to a biomaterial comprising adipose-derived stem cells (ASCs), a ceramic material and an extracellular matrix. In particular, the biomaterial according the present invention secretes osteoprotegerin (OPG), and comprises insulin-like growth factor (IGF1) and stromal cell-derived factor 1-alpha (SDF-1?). The present invention also relates to methods for producing the biomaterial and uses thereof.

Abstract: The present invention relates to a pharmaceutical composition comprising a therapeutically effective amount of (i) at least three miRNAs selected in any one of Table 1, Table 2, Table 3, Table 4, Table 5, Table 6, Table 7, Table 8, Table 9, Table 10, Table 11 or Table 12 and (ii) a pharmaceutical acceptable vehicle. The pharmaceutical composition according to the invention may be of therapeutic use for the prevention and/or the treatment of tissue disorders, including, but not limited to skin disorders, bone disorders and/or cartilage disorders.

Abstract: The present invention relates to a method for assessing, evaluating and/monitoring the purity of a mesenchymal stem cells preparation, in particular of an adipose stem cells preparation, comprising measuring the expression level of at least one growth factor.

Abstract: The present invention relates to a method for assessing, evaluating and/monitoring the purity of a mesenchymal stem cells preparation, in particular of an adipose stem cells preparation, comprising measuring the expression level of at least one growth factor.